ALBIREO PHARMA Shares Outstanding 2007-2021 | ALBO

ALBIREO PHARMA shares outstanding from 2007 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
ALBIREO PHARMA Annual Shares Outstanding
(Millions of Shares)
2020 16
2019 12
2018 12
2017 8
2016 1
2016 2
2015 1
2014 1
2013 1
2012 0
2011 0
2010 0
2009 0
2008 0
2007 0
2006
2006 0
2005
2005 0
ALBIREO PHARMA Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 19
2021-03-31 19
2020-12-31 16
2020-09-30 16
2020-06-30 15
2020-03-31 14
2019-12-31 12
2019-09-30 13
2019-06-30 12
2019-03-31 12
2018-12-31 12
2018-09-30 12
2018-06-30 12
2018-03-31 11
2017-12-31 8
2017-09-30 9
2017-06-30 7
2017-03-31 6
2016-12-31 1
2016-09-30 0
2016-06-30 3
2016-03-31 0
2015-12-31 2
2015-09-30
2015-06-30 2
2015-03-31 1
2014-12-31 1
2014-09-30
2014-06-30 1
2014-03-31 1
2013-12-31 1
2013-09-30
2013-06-30 0
2013-03-31 0
2012-12-31 0
2012-09-30
2012-06-30 0
2012-03-31 0
2011-12-31 0
2011-09-30
2011-06-30 0
2011-03-31 0
2010-12-31 0
2010-09-30
2010-06-30 0
2010-03-31 0
2009-12-31 0
2009-09-30
2009-06-30 0
2009-03-31 0
2008-12-31 0
2008-09-30
2008-06-30 0
2008-03-31 0
2007-12-31 0
2007-09-30
2007-06-30 0
2007-03-31 0
2006-12-31 0
2006-09-30
2006-06-30 0
2006-03-31 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.615B $0.008B
Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29